Balyasny Asset Management’s Emergent Biosolutions EBS Stock Holding History

Balyasny Asset Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,286	Closed	-$127K	–	2902
2024 Q4	$127K	Buy	+13,286	New	+$122K	﹤0.01%	2584
2023 Q1	–	Sell	-1,115	Closed	-$13.2K	–	2776
2022 Q4	$13.2K	Sell	1,115 -545,718	-100%	-$8.45M	﹤0.01%	2531
2022 Q3	$11.5M	Buy	+546,833	New	+$15.2M	0.04%	624
2021 Q1	–	Sell	-30,697	Closed	-$2.75M	–	1837
2020 Q4	$2.75M	Buy	+30,697	New	+$2.82M	0.02%	803
2020 Q2	–	Sell	-56,045	Closed	-$3.24M	–	1211
2020 Q1	$3.24M	Buy	+56,045	New	+$3.23M	0.04%	506
2018 Q2	–	Sell	-6,961	Closed	-$366K	–	1854
2018 Q1	$366K	Buy	+6,961	New	+$347K	﹤0.01%	1550
2016 Q2	–	Sell	-6,031	Closed	-$219K	–	1225
2016 Q1	$219K	Buy	6,031 +600	+11%	+$21.2K	﹤0.01%	1100
2015 Q4	$217K	Buy	+5,431	New	+$189K	﹤0.01%	1077

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's EBS Position: Q1 2025 in Review

Balyasny Asset Management sold out of Emergent Biosolutions (EBS) in Q1 2025, closing a stake of 13,286 shares — an estimated $127K sold.

Balyasny Asset Management first reported a position in EBS in Q4 2015 and held it in 8 quarters. The position peaked at $11.5M in Q3 2022. 160 funds tracked by Wall St. Rank hold EBS as of Q1 2025.

Balyasny Asset Management reported no remaining Emergent Biosolutions position as of Q1 2025 after selling out during the quarter.
Balyasny Asset Management sold 13,286 Emergent Biosolutions shares in Q1 2025, an estimated $127K.
Balyasny Asset Management first reported a position in Emergent Biosolutions in Q4 2015 and held it in 8 quarters.
Balyasny Asset Management's Emergent Biosolutions position peaked at $11.5M in Q3 2022.
160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2025.

Based on Balyasny Asset Management's 13F filing for Q1 2025, filed 15 May 2025.